PRESSEPORTAL Presseportal Logo
All Stories
Subscribe to Gerresheimer AG

04.12.2008 – 07:53

Gerresheimer AG

Gerresheimer ascends to the MDAX

Düsseldorf (ots)

Gerresheimer stock becomes even more attractive through inclusion in MDAX on December 22, 2008

On September 6, 2007 Gerresheimer was already included in the SDAX ahead of the normal scheduling process

Gerresheimer stock will be included in the MDAX Index on December 22, 2008. This was decided by the Management Board of the German Stock Exchange late on Wednesday evening in the course of the review of the selection indices.

Gerresheimer AG has been listed in the Prime Standard of the Frankfurt Stock Exchange since June 11, 2007 after one of the largest IPOs of the year, with a total issue volume in excess of EUR 900 million. Already, on September 6, 2007, Gerresheimer was included in the SDAX Index ahead of the normal scheduling process.

"Inclusion in the index confirms Gerresheimer's outstanding development. As an MDAX constituent our company is now even more attractive for national as well as international investors and attracts the attention of the capital market to an increased degree", says Dr. Axel Herberg, CEO of Gerresheimer AG.

In the first nine months of the financial year 2008 (December 2007 to August 2008), sales increased markedly by 12.3 % to EUR 783.4m (prior year period: EUR 697.4m). Operating results (adjusted EBITDA) to the end of August actually improved by 18.1 % to EUR 146.9m (?124.4m). The adjusted EBITDA margin was 18.8 %, a full percentage point higher than in the comparable period of the prior year.

About Gerresheimer

Gerresheimer employs more than 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR 958m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press:

Relations Burkhard Lingenberg
Director Corporate PR & Marketing
Telephone +49 211 6181-250
Telefax +49 211 6181-241

Contact Investor
Anke Linnartz
Director Corporate Investor Relations
Telephone +49 211 6181-314
Telefax +49 211 6181-121

Original content of: Gerresheimer AG, transmitted by news aktuell